Formulary guidance and transparency from P&T to point of care


Reality Check on Nonmetastatic Prostate Cancer

Market access for nonmetastatic prostate cancer treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, almost 58% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: When the FDA approved Erleada (apalutamide) for the treatment of nonmetastatic castration-resistant prostate cancer on Feb. 14, 2018, it was the first therapy that the agency had approved for that indication. Following the July 30, 2019, approval of Bayer’s Nubeqa (darolutamide), three FDA-approved agents, all oral androgen receptor inhibitors, are available to treat the condition, offering a choice of treatment options
  • Key Findings: The products in this indication are well-reimbursed by payers. Pharmacy and medical policies may require procurement of a drug through a specialty pharmacy by either the patient or the administering doctor

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.